Abbott has introduced the RealTime HCV Genotype II test, the first FDA-approved hepatitis C virus (HCV) genotyping test. The RealTime HCV Genotype II test determines the specific strain of the HCV virus present in the blood of an HCV-infected individual.

According to the CDC, an estimated 3.2 million people in the U.S. have chronic HCV infection, making it a significant health issue.  More than 75% of adults with hepatitis C are baby boomers, most of whom are unaware they are infected.

Once a patient is diagnosed with HCV, a physician would order a hepatitis C genotype test to determine the specific type of HCV-virus the patients is infected with. Genotyping the HCV virus allows physicians to personalize a treatment plan to improve clinical outcomes.

To learn more about the RealTime HCV Genotype II Test, visit